Genitourinary Cancer Clinical Trials

PROSTATE
EA8184: A Phase II Randomized Double Blinded Study of Green Tea Catechins (GTC) vs. Placebo in Men on Active Surveillance for Prostate Cancer: Modulation of Biological and Clinical Intermediate Biomarkers. The purpose of this study is to find out if the study drug (Sunphenon® 90D, which contains green tea catechins) can help prevent progression of prostate cancer from a low risk stage to higher risk stages in men who are on active surveillance. Learn more about the EA8184 trial or call the Reading Hospital Protocol Office at 484-628-8193.
NRG-GU013: The Phase III ‘High Five Trial’ Five Fraction Radiation for High-Risk Prostate Cancer. The purpose of this study is to compare two radiation treatment schedules: one delivers a higher dose of radiation per treatment for fewer treatments over a shorter length of time (stereotactic body radiation therapy [SBRT]); the other delivers a lower dose of radiation per treatment but for more treatments over a longer time. Learn more about the NRG-GU013 trial or call the Reading Hospital Protocol Office at 484-628-8193.
NRG-GU009: Parallel Phase III Randomized Trials For High Risk Prostate Cancer Evaluating De-Intensification For Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation (Predict-RT). The purpose of this study is to use the Decipher risk score (The Decipher risk score is determined by testing the prostate tumor tissue from your biopsy for different genes that predict the risk of your cancer spreading.) to decide if you are assigned to the part of the study comparing more aggressive treatment with the usual treatment for high Decipher risk score prostate cancer or assigned to the part of the study comparing a less aggressive treatment to the usual treatment for low Decipher risk score prostate cancer. Learn more about the NRG-GU009 trial or call the Reading Hospital Protocol Office at 484-628-8193.
NRG-GU010: Parallel Phase III Randomized Trials of Genomic Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE). The purpose of this study is to use the Decipher risk score (The Decipher risk score is determined by testing the prostate tumor tissue from your biopsy for many different genes that all together indicate the risk of your cancer spreading.) to guide intensification (for higher Decipher gene risk) or de-intensification (for low Decipher gene risk) of treatment to better match therapies to an individual patient’s cancer aggressiveness. Learn more about the NRG-GU010 trial or call the Reading Hospital Protocol Office at 484-628-8193.
NRG-GU008: Randomized Phase III Trial Incorporating Abiraterone Acetate with Prednisone and Apalutamide and Advanced Imaging into Salvage Treatment for Patients with Node-Positive Prostate Cancer after Radical Prostatectomy. The purpose of this study is to compare the use of hormone therapy and radiation therapy (usual treatment) to the use of apalutamide and abiraterone acetate with prednisone plus the usual treatment. Learn more about the NRG-GU008 trial or call the Reading Hospital Protocol Office at 484-628-8193.
TJU-17C.072: Prostate cancer outcomes: An international registry to improve outcomes in men with advanced prostate cancer (IRONMAN) The purpose of this study is to learn more about prostate cancer and to describe the use of different therapies for advanced prostate cancer internationally. Learn more about the TJU-17C.072 trial or call the Reading Hospital Protocol Office at 484-628-8193.

PROSTATE

EA8184: A Phase II Randomized Double Blinded Study of Green Tea Catechins (GTC) vs. Placebo in Men on Active Surveillance for Prostate Cancer: Modulation of Biological and Clinical Intermediate Biomarkers.

The purpose of this study is to find out if the study drug (Sunphenon® 90D, which contains green tea catechins) can help prevent progression of prostate cancer from a low risk stage to higher risk stages in men who are on active surveillance.

Learn more about the EA8184 trial or call the Reading Hospital Protocol Office at 484-628-8193.

NRG-GU013: The Phase III ‘High Five Trial’ Five Fraction Radiation for High-Risk Prostate Cancer.

The purpose of this study is to compare two radiation treatment schedules: one delivers a higher dose of radiation per treatment for fewer treatments over a shorter length of time (stereotactic body radiation therapy [SBRT]); the other delivers a lower dose of radiation per treatment but for more treatments over a longer time.

Learn more about the NRG-GU013 trial or call the Reading Hospital Protocol Office at 484-628-8193.

NRG-GU009: Parallel Phase III Randomized Trials For High Risk Prostate Cancer Evaluating De-Intensification For Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation (Predict-RT).

The purpose of this study is to use the Decipher risk score (The Decipher risk score is determined by testing the prostate tumor tissue from your biopsy for different genes that predict the risk of your cancer spreading.) to decide if you are assigned to the part of the study comparing more aggressive treatment with the usual treatment for high Decipher risk score prostate cancer or assigned to the part of the study comparing a less aggressive treatment to the usual treatment for low Decipher risk score prostate cancer.

Learn more about the NRG-GU009 trial or call the Reading Hospital Protocol Office at 484-628-8193.

NRG-GU010: Parallel Phase III Randomized Trials of Genomic Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE).

The purpose of this study is to use the Decipher risk score (The Decipher risk score is determined by testing the prostate tumor tissue from your biopsy for many different genes that all together indicate the risk of your cancer spreading.) to guide intensification (for higher Decipher gene risk) or de-intensification (for low Decipher gene risk) of treatment to better match therapies to an individual patient’s cancer aggressiveness.

Learn more about the NRG-GU010 trial or call the Reading Hospital Protocol Office at 484-628-8193.

NRG-GU008: Randomized Phase III Trial Incorporating Abiraterone Acetate with Prednisone and Apalutamide and Advanced Imaging into Salvage Treatment for Patients with Node-Positive Prostate Cancer after Radical Prostatectomy.

The purpose of this study is to compare the use of hormone therapy and radiation therapy (usual treatment) to the use of apalutamide and abiraterone acetate with prednisone plus the usual treatment.

Learn more about the NRG-GU008 trial or call the Reading Hospital Protocol Office at 484-628-8193.

TJU-17C.072: Prostate cancer outcomes: An international registry to improve outcomes in men with advanced prostate cancer (IRONMAN)

The purpose of this study is to learn more about prostate cancer and to describe the use of different therapies for advanced prostate cancer internationally.

Learn more about the TJU-17C.072 trial or call the Reading Hospital Protocol Office at 484-628-8193.

RENAL
NRG-GU012 - Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (SAMURAI). The purpose of this study is to compare the usual treatment of immune therapy alone to using radiation therapy plus the usual treatment. Learn more about the NRG-GU012 trial or call the Reading Hospital Protocol Office at 484-628-8193.

RENAL

NRG-GU012 - Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (SAMURAI).

The purpose of this study is to compare the usual treatment of immune therapy alone to using radiation therapy plus the usual treatment.

Learn more about the NRG-GU012 trial or call the Reading Hospital Protocol Office at 484-628-8193.